Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute optic neuritis: Unmet clinical needs and model for new therapies.
Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, Cadavid D, Balcer LJ. Galetta SL, et al. Among authors: cadavid d. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135. doi: 10.1212/NXI.0000000000000135. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26236761 Free PMC article. Review.
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators. Cadavid D, et al. Lancet Neurol. 2017 Mar;16(3):189-199. doi: 10.1016/S1474-4422(16)30377-5. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229892 Clinical Trial.
Predictors of response to opicinumab in acute optic neuritis.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L; RENEW Study Investigators. Cadavid D, et al. Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162. doi: 10.1002/acn3.620. eCollection 2018 Oct. Ann Clin Transl Neurol. 2018. PMID: 30349850 Free PMC article.
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study.
Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Cleanthous S, et al. Among authors: cadavid d. Mult Scler J Exp Transl Clin. 2018 May 17;4(2):2055217318776990. doi: 10.1177/2055217318776990. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 29796290 Free PMC article.
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study.
Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Strzok S, et al. Among authors: cadavid d. Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783766. doi: 10.1177/2055217318783766. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 30090638 Free PMC article.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147 Clinical Trial.
125 results